CenterBook Partners LP Increases Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

CenterBook Partners LP boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 182.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,819 shares of the medical research company's stock after buying an additional 7,635 shares during the quarter. CenterBook Partners LP's holdings in Bio-Rad Laboratories were worth $3,883,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of BIO. Metis Global Partners LLC lifted its position in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after purchasing an additional 30 shares in the last quarter. Signaturefd LLC grew its position in Bio-Rad Laboratories by 13.2% in the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after acquiring an additional 31 shares in the last quarter. UMB Bank n.a. boosted its position in Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the period. Thrivent Financial for Lutherans lifted its holdings in shares of Bio-Rad Laboratories by 0.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after buying an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Bio-Rad Laboratories by 3.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after acquiring an additional 34 shares during the period. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Down 2.2 %

Shares of NYSE BIO traded down $5.43 during mid-day trading on Tuesday, reaching $244.19. 103,924 shares of the company's stock traded hands, compared to its average volume of 317,109. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. Bio-Rad Laboratories, Inc. has a 1-year low of $215.38 and a 1-year high of $387.99. The stock has a market cap of $6.84 billion, a P/E ratio of -3.75 and a beta of 1.12. The business has a 50-day simple moving average of $262.86 and a 200 day simple moving average of $314.11.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of "Moderate Buy" and a consensus price target of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.